| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
1,250,000,000 |
| Market
Cap: |
80.34(B) |
| Last
Volume: |
14,507,907 |
Avg
Vol: |
8,705,604 |
| 52
Week Range: |
$63.5 - $87.29 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 500 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 259 |
| Guru Rank Value : 4.6 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines. Co.'s primary areas of focus include viral diseases, inflammatory diseases and oncology. Co.'s products include: Biktarvy® for the treatment of HIV-1 infection in certain patients; Veklury® (remdesivir), for the treatment of Coronavirus Disease 2019 requiring hospitalization; Epclusa® for the treatment of chronic hepatitis C virus infection; Vemlidy® for the treatment of chronic hepatitis B virus infection in adults with compensated liver disease; Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
2,000 |
25,472 |
38,458 |
80,792 |
| Total Sell Value |
$145,920 |
$2,022,270 |
$3,052,046 |
$6,445,296 |
| Total People Sold |
1 |
3 |
3 |
4 |
| Total Sell Transactions |
1 |
5 |
9 |
14 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Martin John C |
Director |
• • – |
2018-06-01 |
4 |
OE |
$23.60 |
$1,180,000 |
D/D |
50,000 |
3,067,762 |
|
- |
|
| Wold Olsen Per |
Director |
• • – |
2018-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,241 |
95,571 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,241 |
54,860 |
|
- |
|
| Wilson Gayle E |
Director |
• • – |
2018-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,241 |
124,499 |
|
- |
|
| Milligan John F |
President and CEO |
• • – |
2018-05-04 |
4 |
OE |
$27.07 |
$2,165,600 |
D/D |
80,000 |
1,294,306 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-05-04 |
4 |
AS |
$65.09 |
$379,885 |
D/D |
(5,836) |
52,619 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-05-04 |
4 |
OE |
$26.62 |
$155,325 |
D/D |
5,836 |
58,455 |
|
- |
|
| Martin John C |
Director |
• • – |
2018-05-01 |
4 |
AS |
$72.19 |
$3,609,660 |
D/D |
(50,000) |
3,017,762 |
|
- |
|
| Martin John C |
Director |
• • – |
2018-05-01 |
4 |
OE |
$23.60 |
$1,180,000 |
D/D |
50,000 |
3,067,762 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-04-27 |
4 |
AS |
$73.91 |
$431,117 |
D/D |
(5,833) |
52,619 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-04-27 |
4 |
OE |
$26.62 |
$155,245 |
D/D |
5,833 |
58,452 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-04-20 |
4 |
AS |
$73.39 |
$430,130 |
D/D |
(5,833) |
52,619 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-04-20 |
4 |
OE |
$26.62 |
$155,245 |
D/D |
5,833 |
58,452 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-04-13 |
4 |
AS |
$75.56 |
$440,741 |
D/D |
(5,833) |
52,619 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-04-13 |
4 |
OE |
$26.62 |
$155,245 |
D/D |
5,833 |
58,452 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-04-06 |
4 |
AS |
$74.47 |
$434,384 |
D/D |
(5,833) |
52,619 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-04-06 |
4 |
OE |
$26.62 |
$155,245 |
D/D |
5,833 |
58,452 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-04-02 |
4 |
AS |
$74.93 |
$437,067 |
D/D |
(5,833) |
52,619 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-04-02 |
4 |
OE |
$26.62 |
$155,245 |
D/D |
5,833 |
58,452 |
|
- |
|
| Martin John C |
Director |
• • – |
2018-04-02 |
4 |
AS |
$72.51 |
$3,656,806 |
D/D |
(50,000) |
3,017,762 |
|
- |
|
| Martin John C |
Director |
• • – |
2018-04-02 |
4 |
OE |
$23.60 |
$1,180,000 |
D/D |
50,000 |
3,067,762 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-03-23 |
4 |
AS |
$75.02 |
$437,588 |
D/D |
(5,833) |
52,619 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-03-23 |
4 |
OE |
$26.62 |
$155,245 |
D/D |
5,833 |
58,452 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-03-16 |
4 |
AS |
$80.09 |
$467,138 |
D/D |
(5,833) |
52,619 |
|
- |
|
| Cogan John Francis |
Director |
• • – |
2018-03-16 |
4 |
OE |
$26.62 |
$155,245 |
D/D |
5,833 |
58,452 |
|
- |
|
1105 Records found
|
|
Page 19 of 45 |
|
|
0.19 (0.3%) 
